[Inhibitors] 2-[(2-oxopropyl)thio]imidazolium derivates_ZEDIRA - 코아사이언스

안녕하세요!

ZEDIRA GmbH 수입/공급 업체 코아사이언스 입니다.

 

자세한 상품 정보 및 관련 문의는 전화 02-858-0328 또는 info@coresciences.co.kr로 문의주시기 바랍니다.

감사합니다!

2-[(2-oxopropyl)thio]imidazolium derivates

​

This class of non-peptidyl, active-site directed molecules was developed by Merck Sharp & Dohme in the 1990s. The active site cysteinyl residue attacks the carbonyl group (1) similar to the glutamine residue. However, the subsequent reaction leads to the release of the complementary thione (2) and the acetonylation of the cysteine (3) (Freund et al., Biochemistry 1994, 33:10109-19).

​

Although the molecules were developed to block coagulation factor XIIIa, the compounds inhibit tissue transglutaminase as well (Barsigan et al., J. Biol. Chem. 1991, 266:22501-9).

​

One candidate out of the series has been evaluated in animal models (e.g., Shebuski et al., Blood 1990, 75:1455-9). Please notice that the authors reported a plasma half-life of only 5 to 10 minutes only.

Zedira offers three derivatives of the thioimidazolium scaffold.

• T101 (L-682.777) is a good blocker of tissue transglutaminase and coagulation factor XIIIa. Both enzymes are inhibited with an IC50 of about 0.25 μM.
• D004 (L-683.685) is a good blocker of tissue transglutaminase and coagulation factor XIIIa. Both enzymes are blocked with an IC50 of about 0.35 μM.
• D003 is a weak blocker of tissue transglutaminase with an IC50 of about 1.0 μM.

Cat. No.	Name	Unit
D003	1,3-Dimethyl-2-[(2-oxopropyl)thio]imidazolium chloride	100 mg
D004	1,3-Dimethyl-4,5-diphenyl-2-[(2-oxopropyl)thio]imidazolium trifluorosulfonic acid salt	10 mg
T101	1,3,4,5-Tetramethyl-2-[(2-oxopropyl)thio]imidazolium chloride	10 mg

​* 본 상품은 오직 연구용으로만 사용 가능합니다. 인체 및 제품화에 사용하실 수 없습니다.

코아사이언스 coresciences​ ZEDIRA GmbH, Darmstadt, Germany Korea 한국 대리점 distributor 트랜스글루타미나제 트랜스글루타미나아제 트랜스글루타미네이스 트랜스글루타미네이즈 활성 분석 측정 키트